TOWARD NONALCOHOLIC FATTY LIVER TREATMENT; A REVIEW ON HERBAL MEDICINE TREATMENT

Fatemeh Mohammadipour1, Massumeh Niazi2, Atefe Veiskaramian3, Yaser Mokhayeri3, Alireza Moayyedkazemi4,*

1Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
2Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran
3Department of Statistics and Epidemiology, Lorestan University of Medical Sciences, Khorramabad, Iran
4Department of Internal Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

Email: armokazemi@gmail.com

Received: 19.11.2019 Revised: 16.12.2019 Accepted: 13.01.2020

Abstract
This study, review the nonalcoholic fatty liver treatment with emphasis on herbal medicine treatment. The accumulation of the mass of triglycerides by 5% in the liver cells of those who are not alcoholic leads to a situation called nonalcoholic fatty liver disease (NAFLD). Nonalcoholic fatty liver is known as the most common liver disorder in the world, such that its prevalence varies from 3% to 25% in different populations of the world per race, age, sex, place of residence and lifestyle. Numerous studies have been carried out on the NAFLD and its pathological mechanism and are still ongoing. In classification of the causes of fatty liver, two general groups can be noted: (i) an effective group with indirect effects such as hypothyroidism, pituitary hypoplasia, polycystic ovarian syndrome, and sleep apnea; (ii) The other group is directly involved in the development of this disease in individuals such as abdominal obesity, metabolic syndrome and type 2 diabetes. Most patients are asymptomatic and are diagnosed by disturbed liver tests. This disease is the most common cause of liver enzymes disorder after hepatitis and chronic liver disease. In more than three-fourths of patients during a clinical examination, the increased size of liver is visible, and the most common symptom is excessive fatigue, lethargy, and pain in the upper right abdomen. The patients may complain of persistent itching, jaundice or complications caused by the increased portal pressure. If the disease leads to liver cirrhosis, hepatomegaly is seen in most cases. In most cases, the patient only finds out about the fatty liver when a regular blood test (generally liver function tests) shows a problem. “Alanine aminotransferase” and “Aspartate aminotransferase” are the most important liver enzymes, and their increase of 1.5-2 times in the tests shows the involvement of liver with this disease. Due to the key role of lipid accumulation in NAFLD progression, inhibition of lipid accumulation is a major focus of anti-NAFLD drug development. A variety of anti-NAFLD agents are currently in preclinical development. Additionally, metformin, statins, and fibrates, are currently being tested as NAFLD treatments in clinical trials. This study aims to review medicinal herbs used to treat NAFLD around the world. The obtained results of the present review investigation demonstrated that 27 medicinal herbs were found that traditionally used to treat NAFLD around the world. The most parts of these plants are leaves, root, and flowers, respectively; whereas these medicinal herbs are most commonly used in countries of Asian and African such as Iran, Pakistan, India and South Africa, etc. The results demonstrated that medicinal herbs have universally used to treat NAFLD. Thus, we can consider them as alternative agents for treatment of NAFLD; nevertheless, more investigations are mandatory to elucidate the precise mechanisms and also toxicity of these plants in human subjects.

Keywords: fatty liver; plant medicine; treatment; traditional medicine

Liver and its tasks
Liver is the largest gland in the body, which plays a role in metabolic activities of body such as digestion, and is responsible for more than 500 vital functions in the body. All blood of the digestive tract collected by the portal vein enters the liver and all the material absorbed from the gastrointestinal tract pass through the liver (1). The other tasks of the liver are the drug metabolism, toxin trapping, and purification of toxins by converting them into harmless materials (2). The participation in hematopoiesis (in the prenatal period), resistance to infections, rapid provision of energy when necessary, are among other liver functions (3). The liver stores the fat, vitamins (particularly vitamins A, D, E, K, B12), mineral salts (iron, folate, copper), and other nutrients. The highly specialized liver tissue regulates different and extensive biochemical reactions (4). The synthesis of albumin, globin, cholesterol, blood coagulation factors, and immune system factors, production of glucose from certain amino acids, glycerol and lactate, synthesis of phospholipids, lipoproteins and triglycerides are only some of the functions of this huge biochemical plant. It is obvious that any disturbance in the liver functioning causes a series of disorders that can cause irreversible damages to this organ followed by the whole body (5).

Nonalcoholic fatty liver
The accumulation of the mass of triglycerides by 5% in the liver cells of those who are not alcoholic leads to a situation called nonalcoholic fatty liver disease (NAFLD) (6). This disease that was first diagnosed by Ludwig et al. in 1980 has several stages, the first of which is liver fat or steatosis. At this stage, fat is accumulated in the liver cells, while there are no signs of inflammation or ulcers. In many patients, this situation does not lead to serious liver disease, but in some, it may become nonalcoholic steatohepatitis (7). The nonalcoholic steatohepatitis is a more serious condition, because it may lead to liver ulcer, and finally, it causes a chronic and irreversible disease called cirrhosis (8). The liver cirrhosis is a dangerous condition that does not have a visible symptom, but with the spread of disease, it causes liver fibrosis, and gradually there is a condition where the liver function is severely impaired and can be associated with the death of the patient (9-10).
It can be noted that in rare cases, this disease can lead to liver cancer. According to estimates, in patients involved with first stage of fatty liver, the likelihood of the disease turning to the liver cirrhosis in the next two decades of life is about 1-2%, but it is reported 5-11% for those who are passing the hepatic steatosis stage (11). This issue clearly notes the necessity for timely diagnosis and treatment of the disease.

Fatty liver is divided into three grades based on progressive stages, which is defined based on ultrasound criteria: grade 1 fatty liver (mild), the liver echogenicity increases slightly and the range of diaphragm and intrahepatic arteries are normal. This stage is in fact the first stage of disease development, which is often controlled easily by medicines. In grade 2 fatty liver (moderate), the liver echogenicity is increased moderately and the range of diaphragm and intrahepatic arteries are slightly faded (14). The conditions that cause false inflammation of fats in hepatocytes or fat accumulation in the interstitial spaces of liver organ gradually lead to this degree of disease. Grade 2 in the liver is a moderate to severe situation that require medical care and can sometimes be dangerous (15-16).

In grade 3 fatty liver (severe), the liver echogenicity is highly increased and the range of diaphragm and intrahepatic arteries and the posterior section of right lobe of liver are faded or are seen in small amounts. Grade 3 is in fact the most serious and advanced stage of the disease and is the state where the liver is exposed to a lot of fat accumulation. At this stage, the inflammation of the liver will occur (16-18). The inflammation in the liver makes the other parts of body come to the aid of liver and circulate the blood in the liver, but the liver is too weak to respond to this help (19). Moreover, at this stage, the arteries and veins are trying to pump nutrients and remove toxins, but the disease has reached a dangerous stage. At this stage, where the liver cirrhosis might occur, there is a very small chance for normal liver function (16-18).

**Epidemiology**

Nonalcoholic fatty liver is known as the most common liver disorder in the world, such that its prevalence varies from 3% to 25% in different populations of the world per race, age, sex, place of residence and lifestyle (20). The prevalence of this disease is highly increasing throughout the world due to being dependent on lifestyle of individuals (21). According to World Health Organization, lifestyle refers a combination of behavioral patterns and individual habits throughout life including nutrition, exercise, smoking, sleep and rest that is caused by the socialization process (22).

The statistics published in Asia indicate a prevalence of 5-18% of the disease (21), and also in accordance to the published statistics, the prevalence of nonalcoholic fatty liver in Iran varies from 2.9% to 30% in the general population, and it reaches 55.8% in patients with type 2 diabetes (23-24). This disease, which often is seen in the age range of 40-60, increases as the age enhance (25). The prevalence of this disease in men is twice as women, and as the age increases, the prevalence in women approaches men, and especially after menopause, the prevalence of fatty liver disease in women has an increasing trend (26). Unfortunately, due to the wrong lifestyle, many children and adolescents are obese, which could make them prone to fatty liver at an earlier age (27). There is a relatively high statistical frequency of fatty liver in children; so in accordance to the studies, the prevalence of this disease in obese children in different communities is 42.6%-77.1% (28-29). If a person has fatty liver at an earlier age, the duration of disease increases, and along with this, the complications of fatty liver will also increase (29).

**Pathophysiology**

Numerous studies have been carried out on the NAFLD and its pathological mechanism and are still ongoing. In a group of studies, the role of vascular disorders in the occurrence of NAFLD is considered. The studies have shown that fatty liver is deprived of proper perfusion. Hence, a role is considered for cellular hypoxia in occurrence of NAFLD. According to this hypothesis, 4 stages are defined for occurrence of NAFLD, including steatosis (fat accumulation in hepatocytes), hepatocyte necrosis (caused by fat toxicity), fat release from hepatocytes (that causes inflammatory reaction), and venous obstruction that eventually causes cirrhosis. The above steps are very similar to histogenesis of artery atherosclerosis (30-34).

In another hypothesis, insulin resistance as the cause of steatosis and steatohepatitis and oxidative factors as the cause of inflammation and disease progression are the factors mentioned in “two-step theory”, and they can be somehow attributed to the cause of disease. It is further explained that in obese people and those with diabetes, the insulin resistance increases the fatty acids in the liver cells, and this accumulation finally can lead to destruction of liver cells and leads to the fatty liver disease. In the condition that insulin resistance occurs, the pancreas is forced to produce additional pancreas (35-37). The excessive increase in insulin in the body is known as X syndrome, which can be seen in fatty liver disease (38). In the scientific literature review, there is a nutritional/genetic model that combines a two-stage theory with biological symptoms of other diseases and factors such as gene and nutrition and evaluates the effect of lifestyle and genetic changes for development of NAFLD pathology as effective factors in the development of this disease (20).

**Causes and risk factors**

In classification of the causes of fatty liver, two general groups can be noted: an effective group with indirect effects. Hypothyroidism, pituitary hypoplasia, polycystic ovarian syndrome, and sleep apnea are examples of this category; although they do not directly cause fatty liver, they can provide the situation for the disease and their control is effective in treatment of disease (20). The other group is directly involved in the development of this disease in individuals; abdominal obesity, metabolic syndrome and type 2 diabetes are more common in people with NAFLD, and their presence increases the likelihood of exacerbation of liver disease (39). In addition, the liver congenital diseases, high blood lipids, intestinal bypass surgery and fast weight loss, malabsorption of protein and calories, liver inflammatory diseases such as hepatitis C, poisoning with toxic substances such as carbon tetrachloride, trichloroethylene, phosphorus and fluoridine, use of some medicines, such as tetracycline, valproic acid, amiodarone, and corticosteroids-containing compounds, care known as the causes and diseases associated with fatty liver. Pregnancy, due to the imbalance of hormones in this period as well as weight gain, is another cause of fatty liver disease (40).
Complications

If the process of liver inflammation does not stop, cirrhosis can lead to events such as accumulation of water in the abdomen (ascites), inflammation of esophageal veins (esophageal varices) that can rupture and bleed, dizziness, drowsiness, and stuttering (liver encephalopathy), liver cancer, end-stage liver failure, which means cessation of liver function. In addition to direct destructive effects on the liver, this disease has a wide range of effects on other important organs of the body (41). The increased risk of chronic kidney diseases, cardiovascular diseases, type 2 diabetes, and colon cancer are among the most important side effects of the disease. Meanwhile, it has been shown in some studies that those with nonalcoholic fatty liver indicate a higher incidence of accumulation of atherosclerotic platelets. According to reports, the incidence of kidney disease in those with fatty liver is 21-54%, while it varies from 3.7 to 24.2% in those without fatty liver. Besides, the likelihood of incidence of adenomatous polyps and colon cancer in those with fatty liver is reported 2-3 times, respectively (41).

Disease symptoms

Most patients are asymptomatic and are diagnosed by disturbed liver tests. This disease is the most common cause of liver enzymes disorder after hepatitis and chronic liver disease. In more than three-fourths of patients during a clinical examination, the increased size of liver is visible, and the most common symptom is excessive fatigue, lethargy, and pain in the upper right abdomen (42). The patients may complain of persistent itching, jaundice or complications caused by the increased portal pressure. If the disease leads to liver cirrhosis, hepatomegaly is seen in most cases. The other symptoms of cirrhosis including spider angioma, splenomegaly ascites, palmar erythema, and asterixis may also appear. In contrast, in rare cases, the course of disease is stopped or even returns to normal state without having any specific treatment for unknown reasons (42-43).

Diagnosis

In most cases, the patient only finds out about the fatty liver when a regular blood test (generally liver function tests) shows a problem. "Alanine aminotransferase" and "Aspartate aminotransferase" are the most important liver enzymes, and their increase of 1.5-2 times in the tests shows the involvement of liver with this disease (44-45). In laboratory tests, several factors can be the sign of insulin resistance, such as increase in Gamma-glutamyltransferase and serum Ferritin. Generally, an increase of about 50% in body iron storage along with other diagnostic symptoms can convince the physician to diagnose fatty liver disease (45). Moreover, the inflammatory biomarkers "TNFα" and "Interleukin 6" can also be referred as serum indicators in diagnosis of fatty liver (46). Meanwhile, in the suspected patients, direct and total Bilirubin, fasting blood sugar, and lipid profiles should be evaluated and monitored. The recent studies have shown that in patients with NAFLD, the plasma indicators of lipid peroxidation, inflammation, and endothelial dysfunction is higher compared to individuals without NAFLD (44). Ultrasound is one of the suitable and available diagnostic methods that is used to prove steatosis. The increased liver echogenicity known as "bright liver" that is seen in the liver affected area is properly visible in ultrasound. However, ultrasound does not play an important role in rejection of steatohepatitis or fibrosis and also has a low accuracy in obese patients (47). Among other diagnostic imaging methods, CT scan and MRI can be pointed out, which often have a higher sensitivity to ultrasound and are, of course, more expensive for the patient. However, none of these techniques can differentiate NASH from steatosis or fibrosis and also show the severity of the disease. What determines fatty liver diagnosis is liver biopsy, which properly shows the extent and severity of liver involvement (40-49). The access to disease progression and its prognosis can be achieved by this method. It is also possible to make decisions on the best treatment method using the results of this diagnostic method. Using this method and other techniques referred above, the fatty liver disease can be differentiated from diseases such as alcoholic hepatitis, viral hepatitis A, B, C, E, drug-induced hepatitis, autoimmune, ischemic, Wilson’s disease, celiac disease, etc (48-49).

Table 1. Some causes and risk factors of NAFLD (40)

| Metabolic disorders | Compounds | Surgery | Drugs | Congenital diseases of the liver | Others |
|---------------------|-----------|---------|-------|---------------------------------|--------|
| Diabetes            | Phosphor  | Removing a large portion of the small intestine | Metotrexate | Galactosemia | Overgrowth of intestinal bacteria |
| Obesity             | Uranium compounds | Stomach shortening or jejunum | L-Asparaginase | Glycogen storage diseases | Severe anemia |
| Increase blood cholesterol | Thallium compounds | | Bleomycin | Homocystinuria | Complete intravenous nutrition |
| Long Hunger         | Chromate  | Tetracycline | Wilson disease | Inflammatory bowel disease |
| Antimoan            | | | | |
|                     | | | | |

Treatment

Those with fatty liver, should first be examined for other diseases, and in case of having other diseases, a proper treatment should be initially conducted and until those diseases are not treated or controlled, the person is prone to fatty liver. In case of non-pharmacological treatment of the disease, it can be said that with control on underlying diseases such as weight loss, blood lipids, diabetes, or discontinuation of the causative drugs, the progression of this disease can be prevented, and in many cases, the reverse course can be followed that leads to treatment of this disease. Although weight loss is noted as the most desirable treatment method in many studies, it should not be overlooked that a sudden weight loss followed by obesity-reducing surgeries can have an entirely reversible effect on the treatment of the disease (50). The use of a proper diet, including intake of low calorie and vitamin-containing foods, minerals, and required proteins can be a proper solution for bodyweight moderation (50-51). The control of underlying metabolic diseases, such as control...
of diabetes and blood lipids in patients with fatty liver, has a beneficial role in improving the disease (52). In patients with irreversible cirrhosis due to NASH, “liver transplantation” could be the only appropriate treatment. However, diseases such as obesity, complications of diabetes, cardiovascular diseases, and fear of post-transplantation complications, might be the limitations for transplantation (53). Due to the key role of lipid accumulation in NAFLD progression, inhibition of lipid accumulation is a major focus of anti-NAFLD drug development (54). A variety of anti-NAFLD agents are currently in preclinical development. Additionally, metformin, statins, and fibrates, are currently being tested as NAFLD treatments in clinical trials. However, these drugs have significant adverse side effects, including enhanced risk of infection and osteoporosis (55-56). Hence, novel treatment candidates with high efficacy and minimal side effects are urgently demanded for the treatment of NAFLD (57).

### Medicinal herbs for fatty liver treatment

The history of treatment of diseases with medicinal herbs is as long as the history of human life on Earth (58). From the very beginning, by virtue of experience and acquired knowledge, according to the requirements throughout the life on Earth, humans have treated themselves with medicinal herbs (58). Despite the fact that the progress in the production of industrial drugs somehow prevents the human beings from paying attention to one of the first and most accessible medical resources, the 20th century is called the return to nature and use of herbal medicines by many pharmaceutical scientists (59). The beneficial properties and limited adverse complications of herbs could be the reason to emphasize their therapeutic role in the treatment of various diseases. In the present literature review, by searching the databases of Web of Science, PubMed, Google scholar EMBASE, Scopus, using the combination of keywords such as “herbal medicines”, “fatty liver”, “medical treatment”, “blood lipid reduction”, we intended to find the articles related to fatty liver and the therapeutic effects of herbal medicines on nonalcoholic fatty liver, the results of which are shown in Table 3.

### Table 2. Some drugs used in the NAFLD treatments

| Antioxidants | Insulin-Sensitive Drugs | Blood lipid lowerers |
|--------------|-------------------------|---------------------|
| Vit E        | Metformin               | statins             |
| Vit C        | Thiazolidinedione       | Gemfibrozil         |
| Betaein      |                         | Colic acids         |
| N-acetyl Cysteine |                  |                     |
| Superoxide dismutase |                              |                     |

### Table 3. Beneficial plants for NAFLD

| Scientific name       | Common name | Family | Part of use       | Reference |
|-----------------------|-------------|--------|-------------------|-----------|
| Spinacia oleracea L.  | Spinach     | Amaranthaceae | Leaves            | 60        |
| Crocus sativus        | Saffron     | Iridaceae | Flower            | 61-62     |
| Ficus carica          | Fig         | Moraceae | Fruit             | 63-64     |
| Malus domestica       | Apple       | Rosaceae | Fruit             | 65        |
| Cydonia oblonga Mill. | Quince      | Rosaceae | Fruit             | 66        |
| Vitis vinifera L.     | Currant     | Vitaceae | Fruit             | 61        |
| Berberis vulgaris     | Barberry    | Berberidaceae | Fruit | 67        |
| Corylus avellana      | Hazelnut    | Betulaceae | Leaves-nuts      | 68        |
| Apium graveolens      | Celery      | Apiaceae | Leaves-stem      | 69        |
| Cicer arietinum L.    | Chickpea    | Fabaceae | Seeds             | 70-71     |
| C. zeylanicum         | Cinnamon    | Lauraceae | Bark - powder and dried flowers | 72-73     |
| Rosa damascene.Mill.  | Iranian Damask Rose | Rosaceae | Flower             | 74        |
| Cucumis melo var. inodorus | Melon | Cucurbitaceae | Fruit | 75        |
| Portulaca oleracea    | Common Purslane | Portulacaceae | Leaves-Flower | 76        |
| Nobilis Laurus        | Bay Laurel (rand) | Lauraceae | Leaves            | 77        |
| Punica granatum       | Pomegranate | Lythraceae | Fruit             | 78-79     |
The obtained results of the present review investigation demonstrated that 26 medicinal herbs were found that traditionally used to treat hypertension around the world. The most parts of these plants are leaves, root, and flowers, respectively; whereas these medicinal herbs are most commonly used in countries of Asian and African such as Iran, Pakistan, India and South Africa, etc. Table 3 shows the medicinal plants that traditionally used to treat hypertension around the world.

| Plant Name                  | Part Used   | Family            |
|----------------------------|-------------|-------------------|
| Beta vulgaris              | Leaves      | Amaranthaceae     |
| Citrus medica L.           | Fruit       | Rutaceae          |
| Daucus carota              | Fruit       | Apiaceae          |
| Asparagus officinalis      | Stem-Flower | Asparagaceae      |
| Cuminum cyminum           | Seeds       | Apiaceae          |
| Nigella Sativa             | Seeds       | Ranunculaceae     |
| Prunus dulcis             | Fruit       | Rosaceae          |
| Zingiber officinale        | Rhizome     | Zingiberaceae     |
| Raphanus sativus L.        | Root-leaves | Brassicaceae      |
| Allium sativum             | Root        | Amaryllidaceae    |
| Cucurbita pepo L. Elaeagnus| Fruit       | Cucurbitaceae     |

Flavonoids
Flavonoids are well-known as a group of phytonutrients, which found in a large number of fruits, vegetables, grains, bark, roots, stems, flowers, etc. Reviews have reported that flavonoids compounds have potential effects on the treatment of chronic diseases such as type 2 diabetes mellitus, cardiovascular and fatty liver diseases via immunomodulatory, anti-inflammatory, and antioxidant properties (104).

One of the most important flavonoid compounds is quercetin which has a broad spectrum of biological properties. Previous studies demonstrated that quercetin has potential effects on fatty accumulation, inflammation, fibrosis, nitrosative/oxidative stress, and insulin resistance related with non-alcoholic fatty liver diseases (105). Recently, Pisonero-Vaquero et al (2015) and Mohan et al (2015) demonstrated that quercetin reduces lipid accumulation in hepatocytes in obese mice probably via modulation of mitochondrial oxidative metabolism; indicating quercetin can considered as a beneficial dietary supplementary to decrease the obesity-induced hepatosteatosis (106).

Another compound which is present in a wide spectrum of plants is rutin. Previously it has been proven that (107) this compound is able to reduce adiposity, recover insulin sensitivity, as well as diminish cardiac remodeling and liver damage in rats with high-fat diet-fed (108). In line with previous study, Fu et al (2014) demonstrated that rutin successfully repressed palmitate-induced macrophage activation and decreased liver fat by repressing transcription of SREBP-1c and CD36 in the liver (109). In addition to this compounds, a number of flavonoids compounds such as pueraria (110), bakcalin (111), luteolin (112), hydroxysafflor yellow A (113), genisten (114-115), silybin (116), isorhamnetin (117), iridin (118), naringin (119), shikonin (120), apigenin (121), kaempferol (122), myricetin (123), and pinocembrin (124), similarly exhibited noteworthy roles in the nafd treatment.

Terpenoids
The terpenoids, also well-known as isoprenoids, indicate a wide range of natural products especially in plant essence, and pigment resins derived from terpenes. These compounds exhibit extensive biological and medicinal applications such as anti-tumor, anti-diabetic, anti-inflammatory, antioxidant, antimicrobial, and analgesic effects (125).

Reviews have shown that many terpenoids compounds including betulinic acid, artemisinin, as well as ursolic acid gentiopicroside (126-127) represented important roles to treat the NAFLD. deMeo et al (2009) demonstrated that betulinic acid by affecting
the AMPK-SREBP signaling pathway (considerable decreases in hepatic AMPK phosphorylation, and improved activation of SREBP1) significantly decrease the hepatic lipid accumulation in mice (128).

Saponins
Saponins as an extensive phytochemical group have a triterpene or steroid aglycone and one or more sugar chains. Many biological activities such as antimicrobial, anti-cancer, and immune modulation have been attributed to these compounds. So far, the role of some saponins compounds such as Dioscin, ginsenoside Rh1, ginsenoside Rg1 and trilltin in the treatment of NAFLD (129). One of the main steroid saponins compounds which broadly exist in plants and herbs is Dioscin. Reviews have demonstrated some medicinal applications including anti-tumor (130), anti-hyperlipidemic (131), and anti-microbial properties (132). Recently, Liu et al. (2015) demonstrated that treatment of mice with Dioscin without loss of appetite and increased physical activity resulted in weight loss, decreases blood lipid levels, reduce liver fat accumulation, liver cholesterol and triglyceride deposition by means of decreasing oxidative stress and inflammation and modulation the MAPK signaling pathway and autophagy (133).

Alkaloids
Alkaloids are class of phytochemicals that generally contain basic nitrogen atoms. Studies demonstrated the various pharmacological activities, such as antimicrobial, anti-inflammatory, analgesic, and anti-tumor effects (134). Reviews have shown that several alkaloids compounds such as berberine, sophocarpine (135), rutecarpine (136) and oxymatrine (137) exhibited potent roles in NAFLD treatment.

Berberine is isolated from the herb Coptis chinensis Franch. and widely used to treat diarrhea and other inflammatory diseases in China (138). Recent studies have proved a new therapeutic function of berberine in metabolic disorders, including obesity and diabetes (139). Berberine can be used as a cholesterol lowering drug through a unique mechanism distinct from statins (140). These studies suggested a potential therapeutic activity of berberine for NAFLD. Liver gene expression profile analysis showed that high fat diet induced hepatic steatosis in rats led to global changes in gene expression, and treatment with berberine reversed this process. Several modules of berberine-regulated genes, including abundant long non-coding RNAs [lncRNAs], were identified by bioinformatics analysis. Among these berberine-regulated genes, we found that the lncRNA MRAK052686 and its associated gene Nr2f2 are implicated in the pathogenesis of NAFLD. Hence, the study provides a new insight into the mechanism of the pharmacological action of berberine in the prevention and treatment of NAFLD. Other alkaloids such as sophocarpine, rutecarpine and oxymatrine (129) also play significant roles in protecting against NAFLD.

Other pure products have been showed to be effective in the treatment of NAFLD, including schisandrin B (141), honokiol (142), rhein (143), and emodin (144). TCM are worthy of further study. This review only summarizes a drop in the bucket, and more Chinese medicines that are useful for the treatment of NAFLD will come to light in the future.

Tannins are natural complex compounds, which are made of polyphenolic chemicals, and are abundant in the peel, leaves, and roots of most plants. Tannins, along with other important biological compounds, such as flavonoids, lead to destruction of free radicals and antioxidant effects, and are used in treatment of oxidative stress and hyperlipidemia (145-146). According to the results of the study by Fallah Hosseini et al., the compounds existing in food supplements and medicinal plants such as tannins, flavonoids, sterols, and other antioxidant compounds can affect the metabolism of lipids by influencing metabolic reactions of various tissues. The increase in metabolism of lipids can be proposed as one of the therapeutic routes for fatty liver (147).

The other effective herbal ingredients, the blood lipid lowering properties of which can be noted based on the studies, are alkalds and terpenoids. Nakay, M et al. reported that major biological compounds including flavonoids, alkalds, and terpenoids have positive effects on lowering the serum levels of liver enzymes as well as improved lipid profile (148).

CONCLUSION:
Fatty liver disease is one of the most important gastrointestinal diseases and largely depends on the lifestyle of individuals, diet, and type of activity. Multi-faceted therapies are considered for the disease, including medicinal and non-medical treatment. In the medicinal treatment, we also find two categories of chemical drugs and herbal medicines. In the present study, we found that the plants from different families have had beneficial effects on the treatment of fatty liver, which is important due to the common and extensive side-effects of chemical drugs, thereby introducing herbal sources as a proper alternative to chemical synthetic drugs. However, this can only be proven by further and comprehensive studies.

Availability of Data and Materials
All data generated or analyzed during this study are included in this published article.

Competing Interests
The authors declare that they have no competing interests

Funding
None.

REFERENCE
1. Haas J.T., Franque S, Stael B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu. Rev. Physiol. 2016;78:181–205. doi: 10.1146/annurev-physiol-021115-105331
2. Franque S.M., van der Graaff D., Kwant W,J. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J. Hepatol. 2016;65:425–443. doi: 10.1016/j.jhep.2016.04.005
3. Vikr-Gomez E, Chalasani N. Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Authors' reply. Aliment Pharmacol Ther. 2019 Oct;50(7):836-837. doi: 10.1111/apt.15488
4. Dogru T, Kirik A, Sonmez A. Letter: metformin treatment and hepatocellular carcinoma risk in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019 Oct;50(7):835-836. doi: 10.1111/apt.15462
5. Shin A, Xu H, Imperiale TF. Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults. BMJ Open Gastroenterol. 2019 Aug 12;6(1):e000322. doi: 10.1136/bmjgast-2019-000322. eCollection 2019.
6. Soderberg C, Stil P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51(2): 595-602.
7. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55(7): 434-8.
8. Fracanzani AL, Tiraboschi S, Pisano G, et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 2016;246:208–13.
9. Bhattachar Je LS, Garzen NP, Cabler PC, et al. Non-alcoholic fatty liver disease: A new and important cardiovascular risk factor? Eur Heart J 2012;33:1190–200.
10. Wong VW, Wong GL, Yeung IC, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiography: A prospective cohort study. Hepatology 2016;63:754–63.

11. Martín-Dominguez V, Gonzalez-Casas R, Mendoza-Jimenez-Ridruejo J, Garcia-Buey L, Moreno-Otero R. Pathogenesis, diagnosis and treatment of nonalcoholic fatty liver disease. Rev Esp Enferm Dig. 2013;105(7):409-20.

12. Kontogianni MD, Tilieli N, Margariti A, Georgoulis M, Deutsch M, Tinikos D, et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr 2013 Sep 7.

13. Oddy WH, Herbertson CE, Jacoby P, Ambrosini GL, O’Sullivan TA, Ayonrinde OT, et al. The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol. 2013;108(5):778-85.

14. El-Koofy N, El-Karakhy S, El-Akel W, et al. Ultrasonography as a non-invasive tool for detection of nonalcoholic fatty liver disease in overweight/obese Egyptian children. Eur J Radiol 2012;81(11):3120-3. Epub 2012/07/24.

15. Rockstroh JK. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV. Curr HIV/AIDS Rep. 2017 Apr;14(2):47-53. doi: 10.1007/s11904-017-0574-2.

16. Streba LA1, Vere CC1, Rogoveanu I1, Streba CT1. Non-alcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.

17. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820–1822.

18. Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinogenesis via non-alcoholic fatty liver disease? World J Gastroenterol. 2014;20:9217–9227.

19. Nascimbeni F, Piai R, Bellentani S, Day CP, Ratzik M, Loria P, et al. Non-alcoholic fatty liver disease: epidemiology and natural history. Rev Recent Clin Trials 2014;9(3):126–133.

20. Zhai JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Dig Dis Sci 2015. E-pub ahead of print.

21. Sobrero AA, Rezvan H, Amini-Kiafiabd S, Dayhim M, Merat S, Poursams A. Prevalence of Nonalcoholic Steatohepatitis in Iran: a population based study. Middle East J Digestive Diseases (MEJDD) 2011;1(2):74-9.

22. Alavian SM, Mohammad-Alizadeh AH, Esma-Ashari F, Ardalan G, Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int 2009;29(2):159-63.

23. Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, et al. Prevalence of nonalcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One 2017;12.

24. Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012;54(5):700-13.

25. Shiasi Arani K, Ghasemi SE, Moravveji SA, Shahpouri Arani A. Frequency of metabolic syndrome and type 2 diabetes among the obese children and adolescents in Kashan during 2009-11. Feyz, Kashan Univ Med Sci Health Serv 2012;16(3):240-7. [in Persian]

26. Gharghani R, Razzaghy Azar M. Prevalence of metabolic syndrome in obese children and adolescents. Med J Tabriz Univ Med Sci Health Serv 2010;32(3):57-61. [in Persian]

27. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54(12):3541–3546.

28. Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008;121(1):72-8.

29. Volzke H, Robinson DM, Kleinie V, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005;11(12):1049–1053.

30. Targher G, Bertolini L, Padovani R, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in dietcontrolled influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51(4):1209–1217.

31. Liu YL, Reeves BL, Bart AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5:4309.

32. Day CP, Sakena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Hepatol Gastroenterol Hepatol 2002; 17(Suppl 3):S377-S384.

33. Awuix J, Stael B. Leptin. Lancet 1998; 351(904):737-42.

34. Yu AS, Keefe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002; 2(1):11-9.

35. Nahid S, H M, Khalilzadeh G, Khezali L, Esteghamati A, Morteza A, Jamali A, et al. Serum oxidized LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 2010; 45(4):321-7.

36. Vajro P, Lenta S, Socha P, Dhwavan A, McKiernan P, Baumann U, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012;54(5):700-13.

37. Jamali R Jamali A. Non-alcoholic fatty liver disease. Feyz, Journal of Kashan University of Medical Sciences, Summer 2010; Vol 14, No 2, Pages 169–181.

38. Suman A, Khullar V, Limaye A. Complications of Non-Alcoholic Fatty Liver Disease. Journal of Hepatology. 2016;64, issue 2, Supplement, Page S573.

39. Hunt CM, Turner MJ, Gifford EJ, Britt RB, Su GL. Identifying and Treating Nonalcoholic Fatty Liver Disease. Fed Pract. 2019;36(1):20–29.

40. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–2273.

41. Jamali R, Khonsari M, Merat S, Khoshrnia M, Jafari E, Bahrami Kafiassy H, El Karh, et al. Persistent alanine aminotransferase elevation in diabetes mellitus: a population-based study. Diabetes 2005;54(12):3541–3546.

42. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Nonalcoholic fatty liver, steatohepatitis, and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54(12):3541–3546.

43. Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008;121(1):72-8.

44. Volzke H, Robinson DM, Kleinie V, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005;11(12):1049–1053.
Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.

49. de Alwis NM, Anstee QM, Day CP. How to Diagnose Nonalcoholic Fatty Liver Disease. Dig Dis. 2016;34 Suppl 1:19-26. doi: 10.1159/000447277. Epub 2016 Aug 22.

50. Jeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, Boniecka L, Shahnazaryan U, Kurylowicz A. Dietary and Pharmaceutical Treatment of Nonalcoholic Fatty Liver Disease. Medicina (Kaunas). 2019;55(5):166. Published 2019 May 20. doi:10.3390/medicina55050166.

51. Livne JE, Schwimmer JB, Van Natta ML, et al. Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial. JAMA. 2011;305(16):1659–1668. doi:10.1001/jama.2011.520.

52. Haufe, S; Engel, S; Kast, P; Böhnke, J; Utz, W; Haas, V; Hermzosdorff, M; Mähler, A; Wiessler, S; Birkenfeld, A-L; et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 2011, 53, 1504–1514.

53. Hung CK, Bodenheimer HC Jr. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018 Feb;22(1):175-187. doi: 10.1016/j.cld.2017.08.012. Epub 2017 Oct 21.

54. Green, C.J.; Hodson, L. The influence of dietary fat on liver fat accumulation. Nutrients 2014, 6, 5018–5033.

55. Sigler MA, Cond gon L, Edwards KL. An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. Clin Med Insights Gastroenterol. 2018;11:1179552218787502. Published 2018 Jul 10. doi:10.1177/1179552218787502.

56. Tziomalos K. Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J Hepatol. 2014;6(10):738–744. doi:10.4255/wjh.v6.i10.738.

57. Del Ben M, Polimeni L, Baratta F, et al. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:8341–8350.

58. Desu BSR, Saekele CH. Anti-hyperlipidemic activity of methanolic extract of Rhinacanthus nasutus. Int J Res Pharm Chem 2013;3(3):700-11.

59. Meydani M, T. Hasan S. Dietary Polyphenols and Obesity. Nutrients 2010, 2, 737–751; doi:10.3390/nu2070737.

60. Dongiovanni P, Lanti C, Riso P, Valenti L. Nutritional therapy for nonalcoholic fatty liver disease. J Nutr Biochem 2016;29:1–11. Available

61. Hosseinizadeh H, Nassiri-Ash M, Avicenna’s (Ibn Sina) the canon of medicine and saffron (Crocus sativus): A review. Phytother Res. 2013;27(4):475–83.

62. Amin A, Hamza AA, Bajbouj K, Ashraf SS, Daoud S. Saffron: a potential candidate for a novel anti-cancer drug against hepatocellular carcinoma. Hepatology. 2011;54(3):857–67.

63. G KM, Pallavi E, B RK, Ramesh M, Venkatesh S. Hepatoprotective activity of Ficus carica Linn. leaf extract against carbon tetrachloride-induced hepatotoxicity in rats. DARU J Pharm Sci. 2007;15(3):162–6.

64. Solomou S, Solomou G, Yalovets Z, Grossman S, Bergman M, Gottlieb HE, et al. Antioxidant activities and anthocyanin content of fresh fruits of common fig (Ficus carica L.). J Agric Food Chem. 2006;54(20):7717–23.

65. Boyer J, Liu RH. Apple phytochemicals and their health benefits. Nutr J. 2004;3(1):5. sativus): A review. Phytother Res. 2013;27(4):475–83.

66. Khobnasabjafari M, Jouyban A. A review of phytochemistry and bioactivity of quince (Cydonia oblonga Mill.). JMedPlants Res [Internet]. 2011;5(16):3577–94.

67. Hermenean A, Popescu C, Ardelean A, Stan M, Hadruga N, Mihali CV, et al. Hepatoprotective effects of Berberis vulgaris L. extract?7: cyclodextrin on carbon tetrachloride-induced acute toxicity in mice. Int J Mol Sci. 2012;13(7):9014–34.

68. Bolling BW, Chen C-YO, McKay DL, Blumberg JB. Tree nut phytochemicals: composition, antioxidant capacity, bioactivity, impact factors. A systematic review of almonds, Brazils, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts. Nutr Res Rev. 2011;24(2):244–75.

69. Li P, Jia J, Zhang D, Xie J, Xu X, Wei D. In vitro and in vivo antioxidant activities of a flavonoid isolated from celery (Apium graveolens L var. dulce). Food Funct [Internet]. 2013;4:2423–2125. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24232123.

70. Xue Z, Gao J, Zhang Z, Yu W, Wang H, Kou X. Anti-hyperlipidemic and Antitumor Effects of Chickpea Albumin Hydrolysate. Plant Foods Hum Nutr. 2012;67(4):393–400.

71. Yang Y, Zhou L, Gu Y, Zang Y, Tang J, Li F, et al. Dietary chickpeas reverse visceral adiposity, dyslipidaemia and insulin resistance in rats induced by a chronic high-fat diet. Br J Nutr [Internet]. 2007;98(4):720–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17666145.

72. Anderson R A. Cinnamon and Glucose Homeostasis. Nutr Today [Internet]. 2014;49(Supplement):S10–1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPT-Landinpage&an=00017285-201409001-00007.

73. Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm Allergy Drug Targets. 2009;8(1):2–10.

74. Himesh S, Nanda S, Singhai AK, Jitender M. Radical scavenging activities and natural indicator activity of Aqueous and ethanolic extract of Rosa damascena. Int J Pharm Sci. 2012;4(SUPPL. 5):581–6.

75. Hidar KJ, Chan SW, Dhuhal DJ, Bhardwaj DM, Dama GY. Anti-hyperlipidemic activity of Gurmar melo fruit peel extracts in high cholesterol diet induced hyperlipidemia in rats. J Complement Med Integr Med 2012;9(1).

76. Al-Okbi SY, Mohamed D a., Hamed TE, Esmail RS. Rice Bran Oil and Pumpkin Seed Oil Alleviate Oxidative Injury and Fatty Liver in Rats Fed High Fructose Diet. Polish J Food Nutr Sci [Internet]. 2014;64(2):127–33. Available from: http://www.degruyter.com/view/j/pjfn.2014.64.issue-2/pjfn-2013-0002/pjfn-2013-0002.xml.

77. Vardapetyan H, Tiratsuyan S, Hovhannisyan A. Hepatoprotective Activity of Leaf Extract of Laurus Nobilis L. against CCL4 Induced Hepatotoxicity in Rats. In: 3rd International Conference on Nanotechnologies and Biomedical Engineering, Springer; 2016. p. 419–23.

78. Monem AEA, Dkhil MA, Al-quraishy S. Studies on the effect of pomegranate ( Punica granatum ) juice and peel on liver and kidney in adult male rats. 2011;9(20):5083–9.

79. Al-Muamar MN, Khan F. Obesity: The preventive role of the pomegranate ( Punica granatum ). Nutrition [Internet]. 2012;28(6):595–604. Available from: http://dx.doi.org/10.1016/j.nut.2011.11.013.

80. Rose MH, Sudha PN, Sudhakar K. EFFECT OF ANTIOXIDANTS AND HEPATOPROTECTIVE ACTIVITIES OF METHANOL EXTRACT OF BEET ROOT ( BETA VULGARIS L. ) AGAINST CARBON TETRACHLORIDE INDUCED HEPATOTOXICITY IN RAT MODELS. Int J Pharm Sci Res. 2014;5(6):2546.

81. Malhotra S, Shulda R, Kulshrestha S, Siddiqui A. Chemical Composition and Antioxidant Activity of Citrus Medica Var. Acidica Essential Oil. J Chem Biol Phys Sci. 2016;6(2):574.

82. Verma S, Thuluvath PJ. Complementary and Alternative Medicine in Hepatology: Review of the Evidence of Efficacy. Clin Gastroenterol Hepatol. 2007;5(4):408–16.

83. Nishizawa M, Kano M, Okuyama T, Okumura T, Ikeya Y. Anti-inflammatory effects of enzyme-treated asparagus extract and its constituents in hepatocytes. Funct Foods Heal Dis. 2016;6(2):91–109.

84. Zi L, Lx Z, Zhu J, Gq L, Sj G, Jp L. Herbal medicines for fatty liver diseases ( Review ). Cochrane Collab [Internet].
nontatherapy. World J Gastroenterol 2015; 21: 10104-10112.

101. Panchal SK, Ward L, Brown L. Ellagic acid attenuates high carbohydrate, high-fat diet-induced metabolic syndrome in rats. Eur J Nutr 2013; 52: 559-568.

102. Guo H, Xia M, Zou T, Ling W, Zhong R, Zhang W. Cyanidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor Fox01. J Nutr Biochem 2012; 23: 349-360.

103. Tori M. Terpenoid Composition and Base Sequences of Ligularia virgaurea (Asteraceae) Grown in the Hengduan Mountain Area in China and a Comment on Drawing Structures. Chem Pharm Bull (Tokyo) 2016; 64: 193-206

104. Qin N, Chen Y, Jin MN, Zhang C, Qiao W, Yue XL, Duan HQ, Niu WY. Anti-obesity and anti-diabetic effects of flavonoid derivative (Fla-CN) via microRNA in high fat diet induced obesity mice. Eur J Nutr Sci 2016; 82: 52-63.

105. Kim CS, Kwon Y, Cheo SY, Hong SM, Yoo H, Goto T, Kawada T, Choi HS, Joe Y, Chung HT, Yu R. Quercetin reduces obesity-induced hepatosteatosis by enhancing mitochondrial oxidative metabolism via heme oxygenase-1. Nutr Metab (Lond) 2015; 12:33

106. MV, Martinez-Flórez S, Fernández A, Benet M, Ocaz JL, Jover R, González-Gallego J, Sánchez-Campos S. Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/akt pathway in a diet-induced mouse model of nonalcoholic fatty liver disease. Mol Nutr Food Res 2015; 59: 879-893.

107. Panchal SK, Poudyal H, Arumugam TV, Brown L. Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet fed rats. J Nutr 2013; 143(1): 179-91.

108. Ok HM, Gebreamanuel MR, Oh SA, Jeon H, Lee WJ, Kwon O. A Root-Based Combination Supplement Containing Pueraia lobat and Rehmannia glutinosa and Exercise Preserve Bone Mass in Ovariectomized Rats Fed a High-Fat Diet. Calcif Tissue Int 2015; 97: 624-633.

109. Fu Y, Luo J, Jia Z, Zhen W, Zhou K, Gilbert E, Liu D. Baicalin Protects against Type 2 Diabetes via Promoting Ilet β-Cell Function in Obese Diabetic Mice. Int J Endocrinol 2014; 2014:846742.

110. Gao M, Ma Y, Liu D. Rutin suppresses palmitic acids-triggered inflammation in macrophages and blocks high fat diet-induced obesity and fatty liver in mice. Pharm Res 2013; 30: 2940-2950.

111. Zhang ZF, Fan SH, Zheng YL, Lu J, Wu DM, Shan Q, Hu B. Truxerutin improves hepatic lipid homeostasis by restoring NAD(+)-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice. Biochem Pharmacol 2014; 91: 74-86.

112. Liu Y, Fu X, Lan N, Li S, Zhang J, Wang S, Li C, Shang Y, Huang T, Zhang L. Luteolin protects against high fat diet-induced cognitive deficits in obesity mice. Behav Brain Res 2014; 267: 178-188.

113. Liu Q, Wang CY, Liu Z, Ma XS, He YH, Chen SS, Bai XY. Hydroxysafflor yellow A suppresses liver fibrosis induced by carbon tetrachloride with high-fat diet by regulating PPAR-γ/p38 MAPK signaling. Pharm Biol 2014; 52: 1085-1093.

114. Susuertepanyaw A, Werawatgano N, Dirviriyaakul P, Klaikeaw N. Genistin Attenuates Nonalcoholic Steatohepatitis and Increases Hepatic PPARγ in a Rat Model. Evid Based Complement Alternat Med 2015; 2015: 509057.

115. Zhang YB, Tan JD, Yang SQ, Guo JP, Zhang X, Sun XX, Na XL, Dai SC. Maternal Genistin Intake Can Reduce Body Weight in Male Offspring. Biomed Environ Sci 2015; 28: 769-772.

116. Loguercio C,Andreone P,Brisc C,Brisc MC,Bugianesi E, Chiaromonte M, Gurico S, Carlucci D, de Sio I, Foresi A Freni MA, Grieco A, Groppo M, Lazzari R, Lobello S, Lorefice E, Margotti M, Miele L, Milani S, Okolicanay S, Palacian G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A,
Sporea I, Sorrentino P, Vecchione R, Tuccillo C, Del Vecchio Blanco C, Federico A. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med 2012; 52: 1658-1665.

117. Zhang Y, Gu M, Cai W, Yu L, Feng L, Zhang L, Zang Q, Wang Y, Wang D, Chen H, Tong Q, Ji G, Huang C. Dietary componentisorhamentin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. Sci Rep 2016; 6: 19288.

118. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, Han CK, Zhuang XJ, Lu Y, Li Xi, Yang SY, Li XY. Irsin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 2019; 5: 557-562.

119. Wang D, Yan J, Chen J, Wu W, Zhu X, Wang Y. Naringin improves Neuronal Insulin Signaling, Brain Mitochondrial Function, and Cognitive Function in High-Fat Diet-Induced Obese Mice. Cell Mol Neurobiol 2015; 35: 1061-1071.

120. Lee H, Bae S, Kim K, Kim W, Chung SL, Yang Y, Yoon Y. Shikonin inhibits adipogenesis by modulation of the WNT/β-catenin pathway. Life Sci 2011; 88: 294-301.

121. Hoek-van den Hil EF, van Schotthorst EM, van der Stelt SW, Hj J, van Vliet M, Venema D, Hollman PC, Riejsens IM, Keijer J. Direct comparison of metabolic health effects of the flavonoids quercetin, hesperetin, epicatechin, apigenin and anthocyanins in high-fat-fed mice. Genes Nutr 2015; 10: 469.

122. Alkalhality H, Moore W, Zhang Y, McMillan R, Wang A, Ali M, Suh KS, Zhen W, Cheng Z, Jia Z, Hulver M, Liu D. Small Molecule Kaempferol Promotes Insulin Sensitivity and Preserved Pancreatic β-Cell Mass in Middle-Aged Obese Diabetic Mice. J Diabetes Res 2015; 2015: 532984.

123. Choi HW, Kang MJ, Lee SJ, Kim JH. Ameliorative effect of myricetin on insulin resistance in mice fed a high-fat, high-sucrose diet. Nutr Res Pract 2014; 8: 544-549.

124. Sang H, Yuan N, Yao S, Li F, Wang J, Fang Y, Qin S. Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in ApoE−/− mice. Acta Pharmacol Sin 2012; 11: 166.

125. Choi YJ, Park SY, Kim JY, Won KC, Kim BR, Son JK, Lee SH, KimYW. Combined treatment of betulinic acid, a PTP1B inhibitor, with Orthosiphon stamineus extract decreases body weight in high-fat-fed mice. J Med Food 2013; 16: 2-8.

126. Jia Y, Kim S, Kim J, Kim B, Wu C, Lee JH, Jun HJ, Kim N, Lee D, Lee SJ. Urosolic acid improves lipid and glucose metabolism in high-fat-fed C57BL/6j mice by activating peroxisome proliferator-activated receptor alpha and hepatic autophagy. Mol Nutr Food Res 2015; 59: 344-354.

127. Kim KE, Ko KH, Heo RW, Yi CO, Shin HJ, Kim JY, Park JH, Nam S, Kim H, Bok GS. Artemisia annua Leaf Extract Attenuates Hepatic Steatosis and Inflammation in High-Fat Diet-Fed Mice. J Med Food 2016; 19: 290-299.

128. de Melo CL, Queiroz MG, Arruda Filho AG, Rodrigues AM, de Sousa DF, Almeida JG, Pessoa OD, Silveira ER, Menezes DB, Melo TS, Santos FA, Rao VS. Betulinic acid, a natural pentacyclic triterpenoid, prevents abdominal fat accumulation in mice fed a high-fat diet. J Agric Food Chem 2009; 57: 8767-8781.

129. Yao H, Qiao YJ, Zhao YL, Tao XF, Xu LN, Yin LH, Qi Y, Peng JY. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(30): 6990-6905.

130. Hsieh MJ, Tsai TL, Hsieh YS, Wang CJ, Chiou HL. Dioscin-induced autophagy mitigates cell apoptosis through modulation of PI3K/Akt and ERK and JNK signaling pathways in human lung cancer cells. Arch Toxicol 2013; 87: 1927-1937.

131. Li H, Huang W, Wen Y, Gong G, Zhao Q, Yu G. Anti-thrombotic activity and chemical characterization of steroidal saponins from Dioscorea zingiberensis C.H. Wright. Fitoterapia 2010; 81:1147-1156.

132. Li M, Han X, Yu B. Synthesis of monomethylated dioscin derivatives and their antioxidant activities. Carbohydr Res 2003; 338: 117-121.

133. Liu M, Xu L, Yin L, Qi Y, Yu Y, Han X, Zhao Y, Sun H, Yao J, Lin Y, Liu K, Peng J. Potent effects of dioscin against obesity in mice. Sci Rep 2015; 5: 7973.

134. Stegelmeier BL, Brown AW, Welch KD. Safety concerns of herbal products and traditional Chinese herbal medicines: dehydroprolylizidine alkaloids and aristolochic acid. J Appl Toxicol 2015; 35: 1433-1437.

135. Zhang Y, Wang S, Li Y, Xiao Z, Hu Z, Zhang J. Sophoracine and matrine inhibit the production of TNF-α and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. Int Immunopharmacol 2008; 8: 1767-1772.

136. Kim SJ, Lee SJ, Lee S, Chae S, Han MD, Mar W, Nam KW. Rutecarpine ameliorates bodyweight gain through the inhibition of orexigenic neuropeptides NPY and AgRP in mice. Biochem Biophys Res Commun 2009; 389: 437-442.

137. Shi L, Shi L, Zhang H, Hu Z, Wang C, Zhang D, Song G. Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation. Mol Med Rep 2013; 8: 439-445.

138. Zhang J, Cao H, Zhang B, Cao H, Xu X, Ruan H, Yi T, Tan L, Qu R, Song G, Wang B, Tu T. Berberine potently attenuates intestinal polyposis growth in ApCMin mice and familial adenomatous polyposis patients through inhibition of Wnt signalling. J Cell Mol Med 2013; 17: 1484-1493.

139. Zhou L, Wang X, Yang Y, Wu L, Li F, Zhang R, Yuan G, Wang N, Chen M, Ning G. Berberine attenuates cAMP-induced lipolysis via reducing the expression of phosphodiesterase in 3T3-L1 adipocytes. Biochem Biophys Acta 2011; 1812: 527-535.

140. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10: 1344-1351.

141. Kwan HY, Niu X, Dai W, Tong T, Chao X, Su T, Chan CL, Lee KC, Fu X, Yi H, Yu H, Li T, Tse AK, Fong WF, Pan SY, Lu A, Yu ZL. Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers. Sci Rep 2015; 5: 9114.

142. Lee JH, Jung JY, Kang JY, Jeong HY, Moon SY, Ku SK, Kang SH, Cho I, Park SJ, Lee JR, Zhao RJ, Kim SC, Kim YW. Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1c pathway. Exp Biol Med (Maywood) 2015; 240:508-518.

143. Zhang Y, Fan S, Hu N, Gu M, Chu C, Li Y, Lu X, Huang C, Rhein Reduces Fat Weight in db/db Mouse and Prevents Diet-Induced Obesity in C57BL/6 Mice through the Inhibition of PPARγ Signaling. PPAR Res 2012; 2012: 374936.

144. Li J, Ding L, Song B, Xiao Q, Xi M, Yang Q, Yang Q, Tang X, Wang Z, Yang L. Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP5 pathway. Eur J Pharmacol 2016; 770: 99-109.

145. King: Throm chung, Tityee wong, Chen- lyee wei, Yao- wen yee huang, Yuan yee lin. Tannins and Human Health review. J Critical reviews in food science and nutrition. Vol 38. Issue 6. August 1998; 421-446.

146. Katia tebin, Lotfi Bitri, Pierre Besancon, Jean-Max Rouanet. Polymeric grape seed tannis prevent plasma cholesterol changes in high- cholesterol fed rats. J food chemistry. Vol 49. 1994; 403-406.

147. Fallah Huseni H, Alavian S, Toliat T, Jamshidi A, Heshmat R, Naghdí Badi H, et al. The efficacy of herbal medicine Khar Maryam (Silybum marianum (L.) Gaertn.) on liver cirrhosis in chronic hepatitis B patients. Journal of Medicinal Plants.2005;1(1):1-6
148. Naczk, M. and Shahidi F. (2006). Phenolics in cereals, fruits, and vegetables: Occurrence, extraction, and analysis. Journal of Pharmaceutical and Biomedical Analysis, 41: 1523 – 1542.

149. Shah P., Bhalodia D., Shelat P. “Nanoemulsion: A Pharmaceutical Review.” Systematic Reviews in Pharmacy 1.1 (2010), 24-32. Print. doi:10.4103/0975-8453.59509

150. Hassanzadeh, J., Mohammadheig, A., Eshrat, B., Moemenbella- Fard, M. Estimation of the regional burden of non-communicable diseases due to obesity and overweight in Markazi province, Iran, 2006-2007(2012) Journal of Cardiovascular Disease Research, 3 (1), pp. 26-31. DOI: 10.4103/0975-3583.91600